Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Where News Facts Matter
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.